Home / Abstract Guidelines & Submission

Abstract Guidelines & Submission

Home / Abstract Guidelines & Submission

Abstract Guidelines & Submission

Abstract submission is now open!

Submit Here

Deadline: 13 January, 2027* (midnight CET)

*After the deadline date, there will be no extension.

Notifications to submitters will be sent by email in March 2027.

Rules for Submission:

  • The presenting authors of oral presentations, posters and clinical case presentations are expected to attend the conference and register for onsite participation.
  • The presenting author is responsible for ensuring that all co-authors are aware of and have approved the abstract content before submission.
  • There is no limit to the number of abstracts an author may submit. However, authors can only present a maximum of 5 abstracts.
  • All abstracts must be submitted and presented in clear English, with accurate grammar and spelling and a standard suitable for publication. If you need help, please arrange for your abstract to be reviewed by a native English-speaking colleague, a university scientific publications office (or similar facility) or a copy editor before submission.

Guidelines:

Participants interested in making an oral or poster presentation are invited to submit an abstract. All abstracts will undergo review by the Abstract Review Committee to determine which abstracts may be accepted.

To submit your abstract, you will first need to register your contact details according to the information provided below under “Writing & Submitting Your Abstract”.

For questions about abstract submission, please contact: ecfs_abstracts@kenes.com.

Accepted abstracts will be invited for presentation in one of the following formats:

Abstracts:
  • Oral presentation
  • Poster in the poster area
  • e-Poster
Clinical Cases:
  • Oral presentation

 

Abstract Submission and Presentation Rules:

Submission
  • All abstracts submitted via the online submission form before the deadline will be forwarded to the Abstract Review Committee for review.
  • Abstracts submitted by fax or email will not be accepted.
  • Please do not submit multiple copies of the same abstract.
  • Maximum Characters: 2,000 characters for abstract submission, including spaces. 3,500 characters for Case Presentations, including spaces. The electronic submission system allows tables; however, each row of a table will deduct 50 characters from the total available for your abstract. A maximum of 2 tables is permitted per abstract. Images must not be included in the abstract submission, but graphs, photographs and other visual materials may be displayed on the corresponding poster at the conference.
Confirmation of Receipt & Notification of Decision
  • You will receive an email confirming receipt of your abstract and indicating the abstract number assigned to it. Please refer to this number in all correspondence regarding your abstract.
  • Please contact the Secretariat if you submit an abstract and do not receive confirmation of receipt.
  • Notifications regarding the status of your abstract will be sent once the review process is complete.
Presentation at Conference
  • Instructions for preparing oral and poster presentations will be sent together with the acceptance notifications.
  • The Abstract Review Committee will endeavour to schedule abstracts according to authors’ preferences but reserves the right to decide on the final presentation format.
  • For each abstract, at least one author is expected to register for the conference. Presenting authors must register by 16 March, 2027.
  • All accepted and presented abstracts for which a presenting author is registered and has paid the registration fee by the deadline will be scheduled for presentation and included in the online Conference Scientific Programme.
  • Accepted abstracts (not Case Presentations) will be included in a supplement to the Journal of Cystic Fibrosis.
  • Abstracts for which no author has registered for the conference by 16 March, 2027 will not be included in the final Conference Scientific Programme.

Writing & Submitting Your Abstract

Please follow the guidance below when writing and submitting your abstract. Failure to do so may result in your abstract receiving a low score, making it unsuitable for further consideration.

Please also consult the ECFS Abstract Submission Style Guide before submitting your abstract.

Abstracts:
  • The abstract should be as informative as possible.
  • Aim: State the background and specific objective of the study.
  • Methods: Briefly describe the methods used, including:
    • Study design and setting, with a clear description of interventions and comparisons.
    • Human studies: characteristics of participants, including number, diagnosis, sex and ethnicity, as appropriate.
    • Animal studies: number of animals, species, strain and genotype, if relevant.
    • Other studies: clear description of materials, such as cell lines and conditions.
    • Type of statistical analyses used.
  • Results: Summarise the results obtained, reporting quantitative data, confidence intervals and p-values for comparisons.
  • Conclusions: State the conclusions reached.

Standard abbreviations may be used.

Physiotherapy Clinical Case Abstracts:
  • Case background and management.
  • Relevant social, clinical, radiological and other information.
  • Problems to be addressed through physiotherapy.
  • Physiotherapy treatment provided.
  • Outcome measures used to establish the effectiveness of physiotherapy treatment.
  • Questions and discussion points highlighted by the case.
Before You Begin, Please Prepare the Following Information:
  • Presenting author’s contact details:
    • Email address
    • Full postal address
    • Phone number
  • Presentation type preference – Please choose one of the options for abstract submission. (For Case presentations only Oral type available) :
    • Oral presentation
    • Poster in the poster area
    • No preference 
  • Author and co-authors’ details:
    • Full first and family names.
    • Affiliation details: department, institution/hospital, city, state (if relevant) and country.
  • Abstract topic – Abstracts must be allocated to a specific topic for the Scientific Programme. Please choose from the ECFS 2027 list of abstract topics.

Abstracts may be reallocated by the Scientific Committee to ensure that sessions are organised consistently.

Diagrams/Tables/Images
  • A maximum of 2 tables is permitted per abstract.
  • Images must not be included in the abstract submission, but graphs, photographs and other visual materials may be displayed on the corresponding poster at the conference.
Declaration of Consent to Publication and Assignment of Copyright
  • I confirm that I have previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and understand that it will be published exactly as submitted.
  • Submission of the abstract constitutes my consent to its publication (e.g. on the conference website, in programmes and in other promotional materials).
  • The Abstract Submitter warrants and represents that he/she is the sole owner of, or has the necessary rights to, all information and content (“Content”) provided to ECFS and Kenes International (hereafter, the “Organisers”). The publication of the abstract does not infringe any third-party rights, including, but not limited to, intellectual property rights.
  • The Abstract Submitter grants the Organisers a royalty-free, perpetual, irrevocable, non-exclusive licence to use, reproduce, publish, translate, distribute and display the Content.
  • The Organisers reserve the right to remove from any publication an abstract that does not comply with the above.
  • I hereby confirm that the contact details saved in this system belong to the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.

For further information, please contact: ecfs_abstracts@kenes.com.

Late-Breaking Abstracts

Late-breaking abstract submission is expected to open in March 2027. The exact dates will be announced later.

Please note that late-breaking abstract submission is not an extension of the regular submission deadline. Late-breaking abstracts must contain new information and results that were not yet known or fully available by the regular abstract submission deadline.

These abstracts must include new, significant and original results obtained after the January submission deadline. This may include results from clinical trials or breakthroughs in fundamental research.

A justification for late submission must be provided as a comment during submission.

The Abstract Review Committee may reject an abstract if it lacks originality or sufficient justification for late submission.